NASDAQ · SPRB
Healthcare · Biotechnology
$47.51
Down-$1.21 (-2.48%)
Updated Sep 29, 2026, 1:00 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SPRB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
SPRB closed at $47.51 after 20 trading sessions, down 19.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $48.28 | $48.99 | $47.01 | $47.51 | 42.37K |
| Sep 25, 2026 | $49.22 | $49.31 | $47.54 | $48.72 | 37.19K |
| Sep 24, 2026 | $49.01 | $49.50 | $47.58 | $49.02 | 85.78K |
| Sep 23, 2026 | $50.50 | $50.735 | $45.01 | $49.415 | 174.77K |
| Sep 22, 2026 | $54.05 | $54.98 | $49.23 | $49.99 | 140.92K |
| Sep 21, 2026 | $53.84 | $55.055 | $53.07 | $53.70 | 97.02K |
| Sep 18, 2026 | $53.04 | $53.86 | $51.80 | $53.05 | 99.66K |
| Sep 17, 2026 | $56.22 | $57.105 | $53.28 | $53.86 | 135.27K |
| Sep 16, 2026 | $55.01 | $56.27 | $53.26 | $54.16 | 100.4K |
| Sep 15, 2026 | $55.99 | $56.36 | $54.51 | $55.165 | 110.11K |
| Sep 14, 2026 | $53.28 | $57.55 | $52.66 | $56.85 | 102.62K |
| Sep 11, 2026 | $54.78 | $56.08 | $53.09 | $53.70 | 88.51K |
| Sep 10, 2026 | $55.61 | $57.50 | $54.03 | $54.35 | 118.76K |
| Sep 9, 2026 | $58.52 | $59.01 | $55.7001 | $55.74 | 96.36K |
| Sep 8, 2026 | $57.39 | $60.51 | $56.60 | $59.09 | 193.05K |
| Sep 4, 2026 | $57.37 | $58.19 | $56.57 | $57.93 | 104.95K |
| Sep 3, 2026 | $59.76 | $60.315 | $57.30 | $57.71 | 116.62K |
| Sep 2, 2026 | $56.52 | $60.13 | $56.52 | $59.67 | 268.14K |
| Sep 1, 2026 | $58.01 | $58.05 | $55.34 | $55.60 | 58.13K |
| Aug 31, 2026 | $60.54 | $60.90 | $57.575 | $58.97 | 44.94K |
The latest Smart Investors Daily articles mentioning SPRB.
SPRB research
Company profile and research snapshot.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Citizens | Market Outperform | — |
| Sep 17, 2026 | Lake Street | Buy | — |
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | Citizens | Market Outperform | — |
| Jul 13, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $180 to $170.
Benzinga · Mar 10, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Buy and maintains $200 price target.
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25) per share which missed the analyst consensus estimate of $(4.22) by 757.99 percent. This is a 15.2 percent increase over
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRB.
